Predictive Oncology Inc（POAI）资讯与事件POAIPredictive Oncology Inc

Axe Compute Renames to Axe Compute Inc. and Will Trade on Nasdaq as AGPU on December 12, 2025

Axe Compute has changed its name to Axe Compute Inc., with its common stock to begin trading on Nasdaq under the ticker symbol AGPU on December 12, 2025. Axe Compute will continue to operate its AI-driven drug discovery business and plans to expand its business into high-performance enterprise AI infrastructure, addressing rising global demand for predictable, scalable compute capacity across enterprise AI workloads. The decision reflects Axe Compute's fundamental observation about the current AI landscape: the bottleneck to AI progress is increasingly infrastructure, not algorithms. While attention concentrates on model capabilities and benchmark performance, Axe Compute believes the enterprises building AI applications face a more immediate problem-access to the compute required to train and run those models at all. Axe Compute plans to operate as an active infrastructure company rather than a passive treasury. The distinction matters: Axe Compute plans to acquire rights to digital assets tied to AI infrastructure-beginning with capacity on the Aethir network- and deploy those assets to serve enterprise clients under service contracts. Axe Compute believes it will be able to derive revenue from token rewards and the margin captured between infrastructure acquisition cost and enterprise billing rates. Axe Compute is not Aethir; Aethir operates the underlying network. Axe Compute intends to monetize access to that network for enterprise buyers who require guaranteed capacity, service-level agreements, and a counterparty that operates within traditional corporate and regulatory structures.

Predictive Oncology Reveals New Appointments to Leadership Team and Board

Predictive Oncology announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir, ATH, token. The Company announced that Shawn Matthews, CEO of DNA Holdings Venture, has joined its Board of Directors; Thomas McLaughlin, CIO of DNA Holdings Venture, has joined the leadership team as Chief Investment Officer; and biopharmaceutical veteran Sara Turken, JD, has joined as the Company's new General Counsel.

Predictive Oncology Sets Pricing for Private Placements to Launch Digital Asset Treasury

The Company plans to raise an aggregate of approximately $344.4 million in two private investment in public equity transactions for the purchase and sale of an aggregate of approximately 66.7 million shares of common stock for a purchase price of $0.7751 per share of common stock for aggregate cash gross proceeds of approximately $51.7M, and pre-funded warrants to purchase up to 223.6 million shares of common stock for a purchase price equal to the Offering Price minus $0.01 per pre-funded warrant in exchange for approximately $292.7 million in notional value representing $173.3 million in discounted value, of in-kind contributions of locked and unlocked Aethir tokens. The pre-funded warrants to be issued in the Crypto PIPE will become exercisable immediately following the Company's receipt of shareholder approval for the exercise of such pre-funded warrants. The PIPEs are expected to close concurrently on or about October 2, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the in-kind contribution of ATH to fund the Company's digital asset treasury strategy and to use the remaining net proceeds from the PIPEs primarily to fund the acquisition of ATH in the open market in further support thereof, as well as for working capital and general corporate purposes. DNA Holdings Venture, Inc. will serve as the Company's strategic advisor and consultant for the Company's digital asset treasury.